Prelude Therapeutics, Inc. (PRLD) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1246322,
    "name": "Prelude Therapeutics, Inc.",
    "stock_name": "Prelude Therapeutics, Inc.",
    "full_name": "Prelude Therapeutics, Inc.",
    "name_url": "stocks-analysis/prelude-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.54",
    "chg": 0.2,
    "chgp": "14.5%",
    "dir": 1,
    "prev_price": "1.34",
    "mcapval": "70.74",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US74065P1012",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "584.2 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/prelude-therapeutics-inc-1246322-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prelude-therapeutics-inc-financial-trend-shifts-from-positive-to-flat-amid-increased-losses-3715755",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PreludeTherapeu_fintrenddot_3715755.png",
        "date": "2025-11-19 15:43:57",
        "description": "Prelude Therapeutics, Inc. has reported a mixed financial performance for the quarter ending June 2025, with increased net profit and sales but significant challenges in operating cash flow and return on capital employed. Despite these hurdles, the company has outperformed the S&P 500 over the past year."
      },
      {
        "title": "Prelude Therapeutics Hits New 52-Week High of $4.22, Marking Significant Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prelude-therapeutics-hits-new-52-week-high-of-422-marking-significant-milestone-3671531",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PreludeTherapeu_priceRelatedfactors_3671531.png",
        "date": "2025-11-04 18:01:47",
        "description": "Prelude Therapeutics, Inc. has achieved a new 52-week high of USD 4.22, significantly up from its low of USD 0.61. Despite this milestone, the company has shown modest one-year performance and remains loss-making, with a market capitalization of USD 71 million and no dividend yield."
      },
      {
        "title": "Is Prelude Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-prelude-therapeutics-inc-technically-bullish-or-bearish-3547730",
        "imagepath": "",
        "date": "2025-09-20 20:01:51",
        "description": "As of 8 September 2025, the technical trend for Prelude Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, while the monthly MACD is also mildly bullish, supporting a positive outlook. The daily moving averages are bullish, further reinforcing this stance. However, the monthly Bollinger Bands and KST are bearish, indicating some caution. The RSI shows a bullish signal on a monthly basis but no signal on the weekly. Overall, the indicators suggest a mildly bullish stance, albeit with some mixed signals.\n\nIn terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a YTD return of -20.78% versus the S&P 500's 12.22%, and a 1Y return of -58.61% compared to 17.14% for the index...."
      },
      {
        "title": "Is Prelude Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-prelude-therapeutics-inc-overvalued-or-undervalued-3544014",
        "imagepath": "",
        "date": "2025-09-20 18:35:09",
        "description": "As of 6 November 2024, Prelude Therapeutics, Inc. has moved from a grade of does not qualify to risky. The company appears to be overvalued given its negative financial metrics and valuation ratios. The Price to Book Value stands at 0.56, the EV to EBIT is at 0.27, and the EV to EBITDA is at 0.28, indicating significant challenges in profitability and valuation relative to its assets.\n\nIn comparison to its peers, Prelude Therapeutics has a less favorable position; for instance, TriSalus Life Sciences, Inc. has a P/E ratio of -6.9780 and an EV to EBITDA of -8.5259, while Seer, Inc. has an EV to EBITDA of 1.1233. Prelude's negative returns are stark, with a year-to-date decline of -20.78% compared to the S&P 500's gain of 12.22%, and a one-year return of -58.61% against the S&P 500's 17.14%. These figures further reinforce the notion that the stock is overvalued in its current state...."
      }
    ],
    "total": 9,
    "sid": "1246322",
    "stock_news_url": "https://www.marketsmojo.com/news/prelude-therapeutics-inc-1246322"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends

2025-11-19 15:43:57

Prelude Therapeutics, Inc. has reported a mixed financial performance for the quarter ending June 2025, with increased net profit and sales but significant challenges in operating cash flow and return on capital employed. Despite these hurdles, the company has outperformed the S&P 500 over the past year.

Prelude Therapeutics Hits New 52-Week High of $4.22, Marking Significant Milestone

2025-11-04 18:01:47

Prelude Therapeutics, Inc. has achieved a new 52-week high of USD 4.22, significantly up from its low of USD 0.61. Despite this milestone, the company has shown modest one-year performance and remains loss-making, with a market capitalization of USD 71 million and no dividend yield.

Is Prelude Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:01:51

As of 8 September 2025, the technical trend for Prelude Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and KST indicators are both mildly bullish, while the monthly MACD is also mildly bullish, supporting a positive outlook. The daily moving averages are bullish, further reinforcing this stance. However, the monthly Bollinger Bands and KST are bearish, indicating some caution. The RSI shows a bullish signal on a monthly basis but no signal on the weekly. Overall, the indicators suggest a mildly bullish stance, albeit with some mixed signals. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a YTD return of -20.78% versus the S&P 500's 12.22%, and a 1Y return of -58.61% compared to 17.14% for the index....

Is Prelude Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:35:09

As of 6 November 2024, Prelude Therapeutics, Inc. has moved from a grade of does not qualify to risky. The company appears to be overvalued given its negative financial metrics and valuation ratios. The Price to Book Value stands at 0.56, the EV to EBIT is at 0.27, and the EV to EBITDA is at 0.28, indicating significant challenges in profitability and valuation relative to its assets. In comparison to its peers, Prelude Therapeutics has a less favorable position; for instance, TriSalus Life Sciences, Inc. has a P/E ratio of -6.9780 and an EV to EBITDA of -8.5259, while Seer, Inc. has an EV to EBITDA of 1.1233. Prelude's negative returns are stark, with a year-to-date decline of -20.78% compared to the S&P 500's gain of 12.22%, and a one-year return of -58.61% against the S&P 500's 17.14%. These figures further reinforce the notion that the stock is overvalued in its current state....

View All News